What are the functions of Serpatinib capsules?

Selpercatinib (Selpercatinib) is a targeted therapy drug mainly used to treat RET fusion-positive non-small cell lung cancer (NSCLC), medullary thyroid carcinoma (MTC) and other solid tumors with RET gene abnormalities. The efficacy of its capsules is mainly reflected in the following aspects:

1.Targeted therapy: Seputinib (Selpatinib) is a highly selective RETkinase inhibitor. By inhibiting the activation of RET protein, it blocks the conduction of abnormal signaling pathways, thereby inhibiting the growth and spread of cancer cells. It has a specific effect on RET tumor cells with abnormal genes and reduces the toxic side effects on normal cells.

2.Remarkable efficacy: Clinical trial data show that Seputinib (serpatinib) has demonstrated significant efficacy in the treatment of RETfusion-positive NSCLC and MTC. For both previously treated patients and treatment-naïve patients, selpatinib showed high objective response rates and sustained response rates, effectively controlling tumor progression.

3.Sustained treatment effect:Selpatinib (serpatinib) The tumor remission effect caused by treatment lasts for a long time, lasting for months or even years in some patients. This provides patients with a sustained and stable chance of survival and extends their survival.

4.Good tolerance: Compared with traditional chemotherapy, sepatinib (serpatinib) has relatively mild adverse effects, and patients generally tolerate the treatment well. Common adverse reactions include hypertension, diarrhea, stomatitis, etc. Most reactions can be alleviated through appropriate management.

5.Personalization of treatment:Selpatinib is a personalized drug that treats patients based on their genotype. It provides precise treatment for tumor patients carrying RET gene abnormalities. This personalized treatment plan can maximize the effectiveness of treatment and reduce unnecessary harm to patients.

Serpotinib capsules, as a targeted therapy, have demonstrated significant efficacy in the treatment of RETfusion-positive NSCLC, MTC and other solid tumors with RET gene abnormalities. It inhibits the growth and spread of tumor cells through targeted effects, significantly improves patients' clinical outcomes and provides patients with new treatment options.